

CC-BY: Experiences from biological and medical publishing

Matthew Cockerill
Managing Director, BioMed Central
STM FACT seminar, Jan 23rd 2012

CC-BY can work

- ◆ BioMed Central, PLoS and Hindawi have used CC-BY for all research articles for many years
- ◆ Springer now uses CC-BY for its OA journals and its OA hybrid option
- ◆ Wiley now uses CC-BY for its OA journals

[Show additional filters](#)**Display Settings:** Summary, 20 per page, Sorted by Recently Added**Send to:** **Filters:** [Manage Filters](#)**Article types**

Clinical Trial

Review

more ...

Text**availability**

Abstract available

Free full text available

Full text available

Publication**dates**

5 years

10 years

Custom range...

Species

Humans

Other Animals

[Clear all](#)[Show additional filters](#)**Results: 1 to 20 of 166368**

<< First < Prev Page 1 of 8319 Next > Last >>

 [rsEGFP2 enables fast RESOLFT nanoscopy of living cells.](#)1. Grotjohann T, Testa I, Reuss M, Brakemann T, Eggeling C, Hell SW, Jakobs S. *elife*. 2012;1:e00248. doi: 10.7554/eLife.00248. Epub 2012 Dec 31.PMID: 23330067 [PubMed - in process] **Free Article**[Related citations](#) [Phylogenetic analysis of pbp genes in treponemes.](#)2. Chadha T, Trindade AA. *Infect Ecol Epidemiol*. 2013;3. doi: 10.3402/iee.v3i0.18636. Epub 2013 Jan 15.

PMID: 23330059 [PubMed - in process]

[Related citations](#) [Children and war: the work of the Children and War Foundation.](#)3. Yule W, Dyregrov A, Raundalen M, Smith P. *Eur J Psychotraumatol*. 2013;4. doi: 10.3402/ejpt.v4i0.18424. Epub 2013 Jan 15.PMID: 23330058 [PubMed - in process] **Free Article**[Related citations](#) [Cryptic Streptococcus mutans 5.6-kb plasmids encode a toxin-antitoxin system for plasmid stabilization.](#)4. Rheinberg A, Swierzy IJ, Nguyen TD, Horz HP, Conrads G. *J Oral Microbiol*. 2013;5. doi: 10.3402/jom.v5i0.19729. Epub 2013 Jan 15.PMID: 23330057 [PubMed - in process] **Free Article**[Related citations](#) [\[Tramadol misuse by adolescents and young adults living on the streets\].](#)

5. Maiga DD, Seyni H, Moussa AO, Sidikou A.

Results by year**Find related data**Database: **Search details**

pmc cc by license[filter]

[See more...](#)**Recent activity**[Turn Off](#) [Clear](#)
PubMed
PubMed[See more...](#)

But?!

- ◆ So I no longer retain absolute control of my work?
- ◆ Someone could re-use my work even in a way that I don't particularly agree with?
- ◆ Someone could combine my work with their own and that of others?
- ◆ **Correct!**

What about moral rights?

From the CC Wiki:

- ♦ CC licenses require that use “must not distort, mutilate, modify or take other derogatory action in relation to the Work which would be prejudicial to the Original Author's honor or reputation.” This prohibits licensees from making uses that would otherwise violate authors’ moral rights of integrity where that right exists. The attribution requirement contained in all of our licenses is intended to satisfy the moral right of attribution.
- ♦ [...] As a general matter, all CC licenses preserve moral rights to the extent they exist (they do not exist everywhere), but allow uses of the work in ways contemplated by the license that might otherwise violate moral rights through a limited waiver or license of the moral rights where that is possible

In practice?

- ◆ Copyright law and moral rights play little (if any) role in academic good practice
- ◆ A determined plagiarist or data-fabricator would hardly be put off by the fact that their action violates copyright
- ◆ Cultural norms and institutionally-enforced sanctions are far more significant

What sort of re-use and interoperability does CC-BY enable?



[Home](#)

[Cases](#)

[Submit case](#)

[About Cases Database](#)

[My Cases Database](#)

Unlock the value of medical case reports

Search 19621 cases from 170 journals

[Go](#)

[Advanced search](#)



Most accessed cases

- Ulcerative colitis associated with the herbal weight loss supplement Hydroxycut
- Intramural esophagic hematoma secondary to coumarinic anticoagulation: a case re...
- Macrophage activation syndrome in a patient with pulmonary inflammatory myofibro...
- Asymmetric graves ophthalmopathy as a sole manifestation of autoimmune hypothyro...

Most shared cases

- Topiramate maculopathy
- Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchy...
- Intramural esophagic hematoma secondary to coumarinic anticoagulation: a case re...
- Peri-orbital foreign body: a case report
- Renal cell cancer without a renal primary

Common searches

- Intervention:Drainage
- Ethnicity:African-American
- Intervention:Appendicectomy
- Medication:Serotonin
- Symptom:Hemorrhage



[Main Page](#)
[Welcome](#)
[Community portal](#)
[Village pump](#)

Language select

English

Select

Participate
[Upload file](#)
[Recent changes](#)
[Latest files](#)
[Random file](#)
[Help](#)
[Contact us](#)
[Donate](#)

Toolbox

User page [Discussion](#)

View [Edit](#) [View history](#)

Search

User:Open Access Media Importer Bot

Welcome

[\[edit\]](#)

This user account is a bot operated by Daniel Mietchen (talk). It is part of the Open Access Media Importer that crawls scholarly publication databases (starting with PubMed Central) for supplementary audio and video files and uploads them to Wikimedia Commons if they are available under licenses compatible with such reuse. The code can be found on [GitHub](#).



It is not a sock puppet, but rather an automated or semi-automated account for making repetitive edits that would be extremely tedious to do manually.

Administrators: if this bot is malfunctioning or causing harm, please [block it](#).

[tasks](#) • [contribs](#) • [count](#) • [logs](#) • [page moves](#) • [block user](#) • [block log](#) • [flag log](#) • [global contribs](#) • [flag bot](#)

This bot was approved at [Commons:Bots/Requests/Open Access Media Importer Bot](#)

Technical details

[\[edit\]](#)

- [Bot request](#)
- Operator: [Daniel Mietchen](#)
- Tasks: upload multimedia files ([10187 so far](#)) from suitably licensed scholarly articles ([gallery](#), [usage](#), [random file](#))
- Mode: run automatically
- Time of operation: continuously
- Maximum edit rate: 6 edits per minute
- Code: <https://github.com/erlehm/erlehm/open-access-media-importer>
- Language: [Python](#)
- Funded by Wikimedia Deutschland as part of the [Wissenswert 2011](#) initiative

Gallery of recently uploaded files

[\[edit\]](#)

See [here](#) for all contributions and [here](#) for a gallery view with more detailed information, e.g. on file categories and licensing, but without teaser image.

Date	Name	Thumbnail	Size	User	Description
17:01, 21 January 2013	Botulinum-Neurotoxins-A-and-E-Undergo-Retrograde-Axonal-Transport-in-Primary-Motor-Neurons-ppat.1003087.s007.ogv (file)		348 KB	Open Access Media Importer Bot	Automatically uploaded media file from Open Access source. Please report problems or suggestions here .
17:00, 21 January 2013	Botulinum-Neurotoxins-A-and-E-Undergo-Retrograde-Axonal-Transport-in-Primary-Motor-Neurons-ppat.1003087.s006.ogv (file)		477 KB	Open Access Media Importer Bot	Automatically uploaded media file from Open Access source. Please report problems or suggestions here .
17:00, 21 January 2013	Botulinum-Neurotoxins-A-and-E-Undergo-Retrograde-Axonal-Transport-in-Primary-Motor-Neurons-ppat.1003087.s005.ogv (file)		40 KB	Open Access Media Importer Bot	Automatically uploaded media file from Open Access source. Please report problems or suggestions here .
17:00, 21 January 2013	Botulinum-Neurotoxins-A-and-E-Undergo-Retrograde-Axonal-Transport-in-Primary-Motor-Neurons-ppat.1003087.s004.ogv (file)		40 KB	Open Access Media Importer Bot	Automatically uploaded media file from Open Access source. Please report problems or suggestions here .
16:58, 21 January 2013	P12-Tethers-the-Murine-Leukemia-Virus-Pre-integration-Complex-to-Mitotic-Chromosomes-ppat.1003103.s003.ogv (file)		398 KB	Open Access Media Importer Bot	Automatically uploaded media file from Open Access source. Please report problems or suggestions here .
				Open	Automatically uploaded



Find content you can share, use and remix

Enter your search query

I want something that I can... use for *commercial purposes*;
 modify, adapt, or build upon.

Search using:

Europeana

Media

Flickr

Image

Fotopedia

Image

Google

Web

Google Images

Image

Jamendo

Music

Open Clip Art Library

Image

SpinXpress

Media

Wikimedia Commons

Media

YouTube

Video

Pixabay

Image

ccMixer

Music

SoundCloud

Music

Please note that search.creativecommons.org is *not* a search engine, but rather offers convenient access to search services provided by other independent organizations. CC has no control over the results that are returned. *Do not assume that the results displayed in this search portal are under a CC license.* You should always verify that the work is actually under a CC license by following the link. Since there is no registration to use a CC license, CC has no

[Add CC Search](#) to your browser.[Learn how](#) to switch to or from CC Search in your Firefox search bar.

Any challenges?

- ◆ Crown Copyright, US Government work, IGOs (WHO, United Nations *etc.*)
- ◆ All need special treatment/wording as normal copyright does not apply
- ◆ But this is true for all licensing, not just Creative Commons
- ◆ And it is soluble...

UK Open Government Licence

This is version 1.0 of the Open Government Licence. The Controller of HMSO may, from time to time, issue new versions of the Open Government Licence. However, you may continue to use Information licensed under this version should you wish to do so.

These terms have been aligned to be interoperable with any Creative Commons Attribution Licence, which covers copyright, and Open Data Commons Attribution License, which covers database rights and applicable copyrights.

Further context, best practice and guidance can be found in the [UK Government Licensing Framework](#) section on The National Archives website.

<http://www.nationalarchives.gov.uk/doc/open-government-licence/>

Why not ND?



VS



Why not ND?

- ◆ Research and scholarship builds on previous work
- ◆ Digital technology facilitates that
- ◆ Restrictive licenses can obstruct it
- ◆ As long as attribution is given, no general reason an author should retain a veto on all future academic work building on their own

Why not NC?

- ◆ The boundaries of commercial use are extremely difficult to define, so NC inevitably creates collateral damage
- ◆ Scholarly journal articles generally do not generate revenue for authors, so authors are not sacrificing income
- ◆ Public funding for research and academic scholarship is intended to benefit all sectors, including commercial

Are monographs different?


- ◆ Scholarly authors may receive royalties on monographs written while under academic employment
- ◆ Such monographs play a larger role in the humanities and social sciences than in STM
- ◆ This is not the only model, nor necessarily the best, but transition away from it may be challenging
- ◆ CC-BY-NC may offer a useful compromise, retaining free distribution and reuse, but preserving the possibility of royalties for print sales

The print monograph model probably needs to evolve anyway

'Niko Pfund, President of Oxford University Press USA, commented at the American Historical Association's January meeting, that historians, more than any other group of scholars, remain "absolutely imprisoned in the format of the printed book," a situation, he believed, was "borderline catastrophic".'

Colin Steele, ANU (quoting the New York Times)

OASPA



OASPA Open Access Scholarly Publishers Association

Home About OASPA Conference Membership Information Resources Blog Contact

Posted on October 23, 2012 by Claire Redhead

Why CC-BY?

At OASPA, one of the criteria for membership is that a publisher must use a liberal license that encourages the reuse and distribution of content. We strongly encourage (but currently do not require) the use of the CC-BY license wherever possible. Given recent moves in the UK by the Wellcome Trust and the Research Councils UK to mandate use of the CC-BY license when funds are used to pay for open access publishing, it is an appropriate moment to consider why CC-BY would be the optimal license for open access publishing.

As emphasized by the early declarations on open access in Budapest, Bethesda and Berlin, open access is about more than access – open access removes access and reuse barriers, and thus has the potential to transform the literature into a much more powerful resource for research, education and innovation. The field of genomics provides a prime example of open access in action.

In June 2011, the Battelle Technology Partnership published a report that estimated the economic impacts of the human genome project. The headline findings were that a \$3.8 billion investment by the US government towards determining the sequence of the human genome helped to drive approximately \$800 billion in economic output and the creation of over 300,000 jobs. Critical to the success of this initiative was making the scientific outputs – the sequence data themselves – openly available to researchers and industry alike to use without restriction.

The human genome project is a compelling demonstration of the power of open access to research, and reflects a well-established practice within the genome community to make research data publicly available for all reuses via resources such as GenBank. It is also interesting that one of the early visionary articles about open access to literature (published in *Science* in 2001) was entitled "Building a GenBank of the published literature", the creation of which would "encourage the development of new, more sophisticated, and valuable ways of using this information, much as GenBank has done for DNA sequences".

To fully realise that potential of open access to research literature, barriers to reuse need to be removed. The Creative Commons licenses have emerged as an effective legal instrument to achieve this. Instead of transferring rights exclusively to publishers (the approach usually followed in subscription publishing), authors grant a non-exclusive license to the publisher to distribute the work, and all users and readers are granted rights to reuse the work.

The most liberal Creative Commons license is CC-BY, which allows for unrestricted reuse of content, subject only to the requirement that the source work is appropriately attributed. Other Creative Commons licenses allow for three possible restrictions to be imposed in addition to the requirement for attribution. In keeping with its tagline "some rights reserved", these are: No Commercial use (NC), No Derivatives (ND) and Share-Alike (SA). Each type of restriction has its uses, for certain types of content and certain types of sharing. But the emerging consensus on the adoption of CC-BY reflects the fact that any of these restrictions needlessly limits the possible reuse of published research.

- ◆ Recommends CC-BY
- ◆ Requires *at least* CC-BY-NC

<http://oaspa.org/why-cc-by/>